Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Net Cash Flow (2016 - 2025)

Viking Therapeutics' Net Cash Flow history spans 12 years, with the latest figure at $65.4 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 377.26% year-over-year to $65.4 million; the TTM value through Dec 2025 reached $139.1 million, up 584.95%, while the annual FY2025 figure was $139.1 million, 584.95% up from the prior year.
  • Net Cash Flow for Q4 2025 was $65.4 million at Viking Therapeutics, down from $66.5 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $140.1 million in Q1 2024 and bottomed at -$151.7 million in Q2 2024.
  • The 5-year median for Net Cash Flow is $5.2 million (2022), against an average of $6.9 million.
  • The largest annual shift saw Net Cash Flow soared 1195.85% in 2023 before it crashed 396.46% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at $15.1 million in 2021, then crashed by 53.11% to $7.1 million in 2022, then skyrocketed by 158.1% to $18.3 million in 2023, then plummeted by 229.08% to -$23.6 million in 2024, then surged by 377.26% to $65.4 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Net Cash Flow are $65.4 million (Q4 2025), $66.5 million (Q3 2025), and -$4.0 million (Q2 2025).